UAB Digital Repository of Documents 1 records found  Search took 0.01 seconds. 
1.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S. (Harvard Medical School) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Tomášek, Jiří (Masaryk University (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (Regne Unit)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A. (Lilly Corporate Center (USA)) ; Hozak, Rebecca R. (Lilly Corporate Center (USA)) ; Ferry, David (Lilly Corporate Center (USA)) ; Caldwell, C. William (Lilly Corporate Center (USA)) ; Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.